Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 4 September 2020.

In the spotlight this week are new trial results in the SGLT2 inhibitor and cardiovascular spaces, antibodies in development for COVID-19, and how the pandemic is affecting consumers' perceptions of healthcare.

Stories mentioned in this episode:

(Also see "DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front" - Scrip, 31 Aug, 2020.)

(Also see "Heart Failure A Key Future Market For Jardiance?" - Scrip, 2 Sep, 2020.)

(Also see "As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran" - Scrip, 1 Sep, 2020.)

(Also see "Regeneron and Roche Await Data On Potential COVID-19 Blockbuster" - Scrip, 3 Sep, 2020.)

(Also see "Post-COVID-19 Consumer Preferences A Guide For Pharma Strategy" - Scrip, 31 Aug, 2020.) 


Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts